- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Zuranolone a reliable drug for post partum depression
Overview
Most new mothers experience postpartum "#depression #babyblues #postpartumdepression
Most new mothers experience postpartum & baby blues& after childbirth, which commonly include mood swings, crying spells, anxiety and difficulty sleeping. Baby blues usually begin within the first 2 to 3 days#depression #babyblues #postpartumdepression
Most new mothers experience postpartum & baby blues& after childbirth, which commonly include mood swings, crying spells, anxiety and difficulty sleeping. Baby blues usually begin within the first 2 to 3 days" after childbirth, which commonly include mood swings, crying spells, anxiety and difficulty sleeping. Baby blues usually begin within the first 2 to 3 days after delivery and may last for up to two weeks.
A pill for postpartum depression led to meaningful improvements in depression symptoms, according to a late-stage study published Wednesday in The American Journal of Psychiatry.
The pill, zuranolone, is not yet approved, but the Food and Drug Administration is expected to make its approval decision by Aug 5.
In the current study included 196 mothers who experienced postpartum depression were split into two groups - half were zuranolone, half given placebo pills for two weeks.
All of the mothers experienced an improvement in their depression symptoms, but those
Gfx on video- Taking the real medication experienced significantly better improvements than those who got the placebo pills
Reference: Kristina M. Deligiannidis,M.D., Samantha Meltzer-Brody et al; Zuranolone for the Treatment of Postpartum Depression, 26 Jul 2023https://doi.org/10.1176/appi.ajp.20220785.